Highlights InnoCan Pharma Corporation

Equities

INNO

CA45783P5085

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 03:59:12 2026-01-12 pm EST			5-day change	1st Jan Change
8.560 ^CAD	0.00%		+5.29%	+27.76%

Jan. 02	InnoCan Pharma to List on NYSE American Next Week	MT
Jan. 02	Innocan Pharma Corp Brief: Anticipates Listing on NYSE American Stock Exchange with Concurrent Offering	MT

Highlights

Jan. 02	InnoCan Pharma to List on NYSE American Next Week	MT
Jan. 02	Innocan Pharma Corp Brief: Anticipates Listing on NYSE American Stock Exchange with Concurrent Offering	MT
Dec. 10	InnoCan Announces Public Filing of Amended Registration Statement For Proposed U.S. Offering	MT
Nov. 27	Innocan Pharma Nine-month Operating Loss Stable, Revenue Fall 10%	MT
Nov. 26	InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 24	Innocan Pharma Corporation Announces Promising Translational Evidence from A Pain Relief Study of Repeated Lpt-Cbd Administration in Goats	CI
25-10-15	Innocan Pharma Corporation Announces Its Patent for Lpt-Cbd Is Allowed in Japan	CI
25-09-18	Innocan Pharma Corporation Partners with Freedom Farm to Bring Remedy and Hope with its LPT-CBD Injection	CI
25-08-29	InnoCan Pharma Plans One-for-65 Share Consolidation Ahead of Nasdaq Listing	MT
25-08-29	Innocan Pharma announces details of proposed share consolidation	RE
25-08-27	InnoCan Pharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-27	Innocan Pharma announces first half of 2025 financial results	RE
25-08-27	Innocan Pharma announces first half of 2025 financial results	RE
25-08-22	Innocan Pharma Corporation to Showcase a Poster Outlining Key Data on LPT-CBD Pharmacokinetics and Efficacy Along with the Recently Published Narrative Review	CI
25-07-23	Innocan Pharma announces public filing of registration statement for proposed U.S. public offering	RE
25-07-23	Innocan Pharma announces public filing of registration statement for proposed U.S. public offering	RE
25-07-03	InnoCan Pharma Corporation Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs	CI
25-06-20	Innocan Pharma Corporation Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference	CI
25-05-28	InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-06	Innocan Pharma Corporation First Granted Patent in Mexico for Its Topical Pain Relief	CI
25-04-15	Innocan Pharma Announces Closing Of Private Placement	RE
25-04-07	Innocan Pharma Corporation Announces Divisional Application for Its Liposomal Liposome-Based CBD Technology Patent	CI
25-03-31	Innocan Pharma Reports Full Year 2024 Results With Revenues More Than Doubling To Us $29.4 Million	RE
25-03-31	Innocan Pharma Reports Full Year 2024 Results With Revenues More Than Doubling To Us $29.4 Million	RE
25-03-31	InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights InnoCan Pharma Corporation

Equities

INNO

CA45783P5085

Pharmaceuticals

Highlights

Filters